Study Finds Medicaid Expanded States Diagnose Breast Cancer at Earlier Stage

Article

A Yale study found that states with expanded Medicaid diagnosed women with breast cancer at an earlier stage of disease and was associated with a reduced number of uninsured patients when compared to non-Medicaid expansion states.

Patients in states with expanded Medicaid coverage through the Affordable Care Act (ACA) saw a higher percentage of women with breast cancer diagnosed at an earlier stage of disease, according to a study published in JAMA Surgery.1-2

More, expansion of Medicaid was associated with both a reduced number of uninsured patients and a decrease in the incidence of advanced-stage breast cancer.1

“If the cancer is diagnosed early, generally treatment is definitive and women have good overall survival,” first author on the study Justin Le Blanc, MD, said in a press release.2 “It's important to get women health care access early. And when patients have access to health care, they're more likely to utilize it.”

The study found an advanced-disease reduction from 21.8% (4603 of 21,127 patients) to 19.3% (4280 of 22,150 patients; P < .001) in expansion states across all races. In non-Medicaid expansion states, the reduction was smaller, from 24.2% (3604 of 14,870 patients) to 23.5% (3072 of 13,088 patients; P = .14).

More, between 2012 and 2016, 4% of the study’s population was uninsured or had Medicaid. In expansion states, the rate of uninsured patients reduced from 22.6% (4771 of 21,127 patients) to 13.5% (2999 of 22,150 patients; P < .001) compared to a reduction from 36.5% (5431 of 14,870 patients) to 35.6% (4663 of 13,088 patients; P = .12) in non-Medicaid expansion states.

Specifically, a particular benefit was observed for African American patients and patients younger than 50 years. Incidence of advanced disease for African American patients decreased from 24.6% (1017 of 4136 patients) to 21.6% (920 of 4259 patients; P < .001) in Medicaid expansion states. More, in non-Medicaid expansion states, the incidence of advanced disease remained at 27% (27.4% [1220 of 4453 patients] to 27.5% [1078 of 3924 patients]; P = .94).

“This result was particularly striking since African American women generally present with more aggressive cancer and decreased survival rates,” senior author Tristen Park, MD, said in a press release.2 “Again, no significant changes were observed in diagnosis stage among this population in non-expansion states.”

A total of 1,796,902 women were included in the study population. The group of researchers analyzed women with breast cancer from 31 Medicaid expansion states and 14 non-Medicaid expansion states. The study employed the American College of Surgeons National Cancer Database, comparing pre-expansion data (2012-2013) to post-expansion data (2015-2016) to assess Medicaid expansion in 2014.

Data from 2007 to 2016 was assessed to analyze the relationship between breast cancer stage and race, age, and insurance status.

Moving forward, the Yale researchers plan to compare the medical services provided to Medicaid insurance patients versus medical services for patients with other insurances or no insurance at all.

In the United States, breast cancer is the most common type of cancer among women. Breast cancer is estimated to account for 279,100 diagnoses and 42,170 deaths in the United States this year.

“Most women with breast cancer live quite a long time if it's caught early and treated correctly. The next step is that we should also try to give them a good quality of life,” Park said in a press release.2

References:

1. Le Blanc JM, Heller DR, Friedrich A, et al. Association of Medicaid Expansion Under the Affordable Care Act With Breast Cancer Stage at Diagnosis. JAMA Surg. doi:10.1001/jamasurg.2020.1495.

2. Yale study: Breast cancer found earlier in states with expanded Medicaid [news release]. Yale News. Published July 1, 2020. https://news.yale.edu/2020/07/01/yale-study-breast-cancer-found-earlier-states-expanded-medicaid. Accessed July 21, 2020.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.